前列地尔联合雷公藤多苷治疗慢性肾炎的临床研究(1)
【摘要】 目的：探讨前列地尔联合雷公藤多苷治疗慢性肾炎的临床疗效。方法：选取本院收治的慢性肾炎患者94例，按照随机数字表法分为治疗组和对照组，每组各47例。对照组给予雷公藤多苷治疗，治疗组给予雷公藤多苷联合前列地尔治疗，比较两组临床治疗效果。结果：治疗前，两组BUN、SCr、Uβ2-MG和24 h尿蛋白定量水平比较，差异均无统计学意义(P>0.05)；与治疗前比较，两组BUN、SCr、Uβ2-MG和24 h尿蛋白定量水平均有明显下降，差异均有统计学意义(P<0.05)；治疗后，治疗组BUN、SCr、Uβ2-MG和24 h尿蛋白定量水平均明显低于对照组，差异均有统计学意义(P<0.05)；治疗组总有效率为91.49%，明显高于对照组的76.60%，差异有统计学意义(P<0.05)。结论：前列地尔联合雷公藤多苷治疗慢性肾炎，可明显减少尿蛋白，延缓肾功能损害，疗效显著，值得临床推广应用。
【关键词】 前列地尔； 雷公藤多苷； 慢性肾炎； 临床研究
【Abstract】 Objective：To explore the clinical efficacy of Alprostadil combined with Tripterygium glycosides in the treatment of chronic nephritis.Method：A total of 94 cases with chronic nephritis in our hospital were selected and divided into the treatment group and the control group according to random number table method，47 cases in each group.The control group was given tripterygium glycosides treatment，while the treatment group was given treatment of alprostadil combined with tripterygium glycosides.The clinical efficacy of two groups were observed and compared.Result：There were no statistical significance in the BUN，SCr，Uβ2-MG and 24 h urinary protein levels of two groups before treatment(P>0.05)；but the BUN，SCr，Uβ2-MG and 24 h urinary protein levels of two groups after treatment were significantly lower than before treatment(P<0.05)；after treatment，the BUN，SCr，Uβ2-MG and 24 h urinary protein levels of the treatment group were significantly lower than the control group(P<0.05)；the overall effective rate of the treatment group was 91.49% obviously higher than the control group of 76.60%，the difference had statistically significant(P<0.05).Conclusion：Alprostadil combined with Tripterygium glycosides in the treatment of chronic nephritis can effectively reduce urine protein，and delay kidney functional lesion，the curative effect is remarkable，it is worthy of clinical application.
【Key words】 Alprostadil； Tripterygium glycosides； Chronic nephritis； Clinical study
First-author’s address：Yingtan People’s Hospital，Yingtan 335000，China
doi：10.3969/j.issn.1674-4985.2017.28.034
慢性腎小球肾炎的临床表现主要为蛋白尿、血尿、水肿和高血压，其发病机制主要与免疫介导有关，该疾病是导致肾衰竭的主要原因[1]。在疾病的治疗方面，目前主要采用降血压、利尿以及预防感染等手段，尚缺乏特效药物。本研究回顾性分析98例慢性肾炎患者临床资料，探讨前列地尔联合雷公藤多苷的临床治疗效果，现报道如下。
1 资料与方法
1.1 一般资料 选取2016年3月-2017年3月本院收治的慢性肾炎患者94例，纳入标准：符合慢性肾炎诊断标准[2]；年龄18～65岁；血肌酐≤442 μmol/L。排除标准：疾病由于系统性红斑狼疮或药物性肾损害等因素引起；由于家族遗传发病；合并有心、脑、肝和造血系统等疾病者；合并肿瘤患者。94例患者按照随机数字表法分为治疗组和对照组，每组各47例。治疗组男29例，女18例；年龄20～64岁，平均(38.71±9.60)岁；病程0.4～11年，平均(4.13±1.95)年；体重42～72 kg，平均(55.12±13.42)kg。对照组男27例，女20例；年龄19～63岁，平均(37.96±9.19)岁；病程, http://www.100md.com(孙龙春 张冬梅 汪广凤)
【关键词】 前列地尔； 雷公藤多苷； 慢性肾炎； 临床研究
【Abstract】 Objective：To explore the clinical efficacy of Alprostadil combined with Tripterygium glycosides in the treatment of chronic nephritis.Method：A total of 94 cases with chronic nephritis in our hospital were selected and divided into the treatment group and the control group according to random number table method，47 cases in each group.The control group was given tripterygium glycosides treatment，while the treatment group was given treatment of alprostadil combined with tripterygium glycosides.The clinical efficacy of two groups were observed and compared.Result：There were no statistical significance in the BUN，SCr，Uβ2-MG and 24 h urinary protein levels of two groups before treatment(P>0.05)；but the BUN，SCr，Uβ2-MG and 24 h urinary protein levels of two groups after treatment were significantly lower than before treatment(P<0.05)；after treatment，the BUN，SCr，Uβ2-MG and 24 h urinary protein levels of the treatment group were significantly lower than the control group(P<0.05)；the overall effective rate of the treatment group was 91.49% obviously higher than the control group of 76.60%，the difference had statistically significant(P<0.05).Conclusion：Alprostadil combined with Tripterygium glycosides in the treatment of chronic nephritis can effectively reduce urine protein，and delay kidney functional lesion，the curative effect is remarkable，it is worthy of clinical application.
【Key words】 Alprostadil； Tripterygium glycosides； Chronic nephritis； Clinical study
First-author’s address：Yingtan People’s Hospital，Yingtan 335000，China
doi：10.3969/j.issn.1674-4985.2017.28.034
慢性腎小球肾炎的临床表现主要为蛋白尿、血尿、水肿和高血压，其发病机制主要与免疫介导有关，该疾病是导致肾衰竭的主要原因[1]。在疾病的治疗方面，目前主要采用降血压、利尿以及预防感染等手段，尚缺乏特效药物。本研究回顾性分析98例慢性肾炎患者临床资料，探讨前列地尔联合雷公藤多苷的临床治疗效果，现报道如下。
1 资料与方法
1.1 一般资料 选取2016年3月-2017年3月本院收治的慢性肾炎患者94例，纳入标准：符合慢性肾炎诊断标准[2]；年龄18～65岁；血肌酐≤442 μmol/L。排除标准：疾病由于系统性红斑狼疮或药物性肾损害等因素引起；由于家族遗传发病；合并有心、脑、肝和造血系统等疾病者；合并肿瘤患者。94例患者按照随机数字表法分为治疗组和对照组，每组各47例。治疗组男29例，女18例；年龄20～64岁，平均(38.71±9.60)岁；病程0.4～11年，平均(4.13±1.95)年；体重42～72 kg，平均(55.12±13.42)kg。对照组男27例，女20例；年龄19～63岁，平均(37.96±9.19)岁；病程, http://www.100md.com(孙龙春 张冬梅 汪广凤)